What supplements or medications can increase CYP2D6 (cytochrome P450 2D6) metabolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 5, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Supplements and Medications That Increase CYP2D6 Metabolism

Rifampin (rifampicin) is the most potent medication for increasing CYP2D6 metabolism through enzyme induction, while St. John's Wort is the most significant herbal supplement that can enhance CYP2D6 activity. 1, 2, 3

Medications That Induce CYP2D6

Strong Inducers

  • Rifampin (rifampicin) - Most potent inducer of CYP enzymes including CYP2D6 3
    • Mechanism: Induces drug metabolizing enzymes and transporters
    • Clinical impact: Can significantly decrease plasma concentrations of CYP2D6 substrates

Moderate to Weak Inducers

  • Anticonvulsants 2, 3
    • Carbamazepine
    • Phenobarbital
    • Phenytoin
  • Dexamethasone (at high doses)

Herbal Supplements That Induce CYP2D6

  • St. John's Wort (Hypericum perforatum) 2
    • Mechanism: Induces multiple CYP enzymes including CYP2D6
    • Clinical impact: Can decrease levels of CYP2D6 substrates by 20-40%

Clinical Implications of CYP2D6 Induction

Reduced Efficacy of CYP2D6 Substrates

When CYP2D6 metabolism is increased, medications metabolized by this enzyme may have:

  • Decreased plasma concentrations
  • Reduced therapeutic effects
  • Potential treatment failure

Common CYP2D6 Substrates Affected 4, 5, 6, 7

  • Antidepressants:
    • Tricyclic antidepressants (nortriptyline, imipramine)
    • SSRIs (fluoxetine, paroxetine)
    • Venlafaxine
  • Antipsychotics:
    • Risperidone
    • Haloperidol
  • Beta-blockers:
    • Metoprolol
    • Propranolol
    • Carvedilol
  • Opioid analgesics:
    • Codeine (reduced conversion to morphine)
    • Tramadol
    • Oxycodone
  • Other medications:
    • Atomoxetine (ADHD medication) 8
    • Ondansetron (antiemetic)

Monitoring and Management

Recommended Monitoring

  • Monitor for decreased efficacy of CYP2D6 substrate medications
  • Consider therapeutic drug monitoring when available
  • Assess for return of symptoms when adding CYP2D6 inducers

Management Strategies

  1. Dose adjustment: Increase dose of CYP2D6 substrates when used with inducers
  2. Alternative medications: Consider drugs not metabolized by CYP2D6
  3. Timing: Separate administration times when possible
  4. Avoid combinations: For narrow therapeutic index drugs

Special Considerations

Genetic Variations

CYP2D6 activity varies significantly among individuals due to genetic polymorphisms 7:

  • Ultrarapid metabolizers (UMs)
  • Extensive metabolizers (EMs)
  • Intermediate metabolizers (IMs)
  • Poor metabolizers (PMs)

Adding inducers to UMs or EMs may cause more pronounced effects than in PMs.

Prodrugs

Some medications require CYP2D6 for conversion to active metabolites 6, 7:

  • Codeine → morphine
  • Tramadol → O-desmethyltramadol

Inducers may paradoxically increase the effects of these prodrugs by enhancing conversion to active metabolites.

Caution with Multiple CYP Interactions

Many medications that induce CYP2D6 also affect other CYP enzymes:

  • Rifampin induces CYP3A4, CYP1A2, CYP2C8, CYP2C9, and CYP2C19 3
  • St. John's Wort affects multiple CYP enzymes and P-glycoprotein 9

This can lead to complex drug interactions requiring careful management.

Pitfalls and Caveats

  • Delayed effect: Enzyme induction takes time (typically 1-2 weeks) to reach maximum effect
  • Prolonged effect: Induction may persist for 1-2 weeks after discontinuation of the inducer
  • Substrate-dependent effects: The magnitude of induction varies among different CYP2D6 substrates
  • Polypharmacy risks: Patients on multiple medications are at higher risk for clinically significant interactions 10
  • Dietary factors: Some dietary components may modestly affect CYP enzyme activity 11

Always consult drug interaction databases and consider pharmacogenetic testing in cases where CYP2D6 metabolism significantly impacts drug efficacy or safety.

References

Guideline

use of dietary supplements in living kidney donors: a critical review.

American Journal of Kidney Diseases, 2020

Research

Metabolic mechanisms of drug-nutrient interactions.

Federation proceedings, 1985

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.